Immunic Other Assets vs Current Deferred Revenue Analysis

IMUX Stock

USD 1.22 0.04 3.17%

Immunic financial indicator trend analysis is infinitely more than just investigating Immunic recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Immunic is a good investment. Please check the relationship between Immunic Other Assets and its Current Deferred Revenue accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment.

For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.

Other Assets vs Current Deferred Revenue

Other Assets vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Immunic Other Assets account and Current Deferred Revenue. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Immunic's Other Assets and Current Deferred Revenue is -0.43. Overlapping area represents the amount of variation of Other Assets that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Immunic, assuming nothing else is changed. The correlation between historical values of Immunic's Other Assets and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Assets of Immunic are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Other Assets i.e., Immunic's Other Assets and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

-0.43

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Other Assets

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Immunic's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Immunic current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment.

For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.Selling General Administrative is likely to drop to about 14 M in 2024. Issuance Of Capital Stock is likely to drop to about 810.4 K in 2024

	2021	2022	2023	2024 (projected)
Net Interest Income	66K	1.0M	3.1M	3.2M
Interest Income	66K	1.0M	3.1M	3.2M

Net Interest Income Interest Income

Immunic fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Short Term Investments	Non Currrent Assets Other	Common Stock Total Equity	Common Stock	Net Tangible Assets	Retained Earnings Total Equity
Total Assets		0.31	0.21	0.39	0.96	0.21	-0.95	-0.04	0.57	0.96	0.6	0.96	0.41	-0.62	0.55	0.33	-0.53	0.21	0.97	-0.23	-0.48	-0.53	0.28	0.28	0.34	0.05
Short Long Term Debt Total	0.31		0.63	0.69	0.21	-0.04	-0.31	-0.58	0.2	0.34	-0.16	0.37	0.82	-0.22	0.38	0.56	0.05	-0.04	0.39	-0.03	0.06	-0.45	0.56	0.56	0.47	-0.51
Other Current Liab	0.21	0.63		0.92	0.12	0.28	-0.27	-0.6	0.41	0.33	-0.32	0.33	0.74	-0.41	0.06	0.4	-0.07	0.28	0.31	-0.18	-0.38	-0.4	0.59	0.6	0.28	-0.56
Total Current Liabilities	0.39	0.69	0.92		0.27	0.09	-0.34	-0.6	0.39	0.41	0.0	0.4	0.91	-0.46	0.39	0.45	-0.08	0.09	0.42	-0.07	-0.42	-0.56	0.57	0.58	0.31	-0.46
Total Stockholder Equity	0.96	0.21	0.12	0.27		0.28	-0.94	-0.04	0.55	0.93	0.59	0.92	0.26	-0.75	0.51	0.38	-0.73	0.28	0.93	-0.14	-0.6	-0.55	0.33	0.32	0.18	0.03
Property Plant And Equipment Net	0.21	-0.04	0.28	0.09	0.28		-0.43	0.06	0.67	0.42	-0.38	0.41	-0.19	-0.34	-0.09	0.04	-0.35	1.0	0.37	-0.58	-0.32	0.24	0.19	0.19	0.17	-0.11
Net Debt	-0.95	-0.31	-0.27	-0.34	-0.94	-0.43		0.03	-0.68	-0.99	-0.39	-0.99	-0.29	0.63	-0.41	-0.34	0.56	-0.43	-0.98	0.34	0.49	0.44	-0.36	-0.36	-0.36	0.05
Retained Earnings	-0.04	-0.58	-0.6	-0.6	-0.04	0.06	0.03		0.13	-0.07	0.24	-0.07	-0.64	0.4	-0.24	-0.88	0.19	0.06	-0.09	-0.15	0.3	0.64	-0.83	-0.84	0.12	0.86
Accounts Payable	0.57	0.2	0.41	0.39	0.55	0.67	-0.68	0.13		0.69	0.03	0.67	0.21	-0.44	0.19	-0.03	-0.33	0.67	0.65	-0.33	-0.41	-0.18	0.24	0.24	0.3	0.01
Cash	0.96	0.34	0.33	0.41	0.93	0.42	-0.99	-0.07	0.69		0.38	0.99	0.36	-0.64	0.42	0.35	-0.54	0.42	0.99	-0.34	-0.5	-0.47	0.38	0.38	0.36	-0.08
Non Current Assets Total	0.6	-0.16	-0.32	0.0	0.59	-0.38	-0.39	0.24	0.03	0.38		0.35	0.12	-0.27	0.43	0.02	-0.3	-0.38	0.39	0.27	-0.33	-0.43	-0.19	-0.2	-0.03	0.53
Cash And Short Term Investments	0.96	0.37	0.33	0.4	0.92	0.41	-0.99	-0.07	0.67	0.99	0.35		0.37	-0.63	0.43	0.35	-0.53	0.41	1.0	-0.36	-0.44	-0.45	0.37	0.37	0.38	-0.09
Common Stock Shares Outstanding	0.41	0.82	0.74	0.91	0.26	-0.19	-0.29	-0.64	0.21	0.36	0.12	0.37		-0.33	0.52	0.53	0.03	-0.19	0.4	0.03	-0.2	-0.62	0.51	0.52	0.39	-0.43
Non Current Liabilities Total	-0.62	-0.22	-0.41	-0.46	-0.75	-0.34	0.63	0.4	-0.44	-0.64	-0.27	-0.63	-0.33		-0.34	-0.55	0.92	-0.34	-0.63	-0.12	0.87	0.67	-0.56	-0.57	0.2	0.32
Other Current Assets	0.55	0.38	0.06	0.39	0.51	-0.09	-0.41	-0.24	0.19	0.42	0.43	0.43	0.52	-0.34		0.4	-0.22	-0.09	0.51	-0.06	-0.2	-0.42	0.32	0.32	0.23	-0.18
Other Stockholder Equity	0.33	0.56	0.4	0.45	0.38	0.04	-0.34	-0.88	-0.03	0.35	0.02	0.35	0.53	-0.55	0.4		-0.42	0.04	0.38	0.04	-0.39	-0.7	0.86	0.86	0.0	-0.73
Total Liab	-0.53	0.05	-0.07	-0.08	-0.73	-0.35	0.56	0.19	-0.33	-0.54	-0.3	-0.53	0.03	0.92	-0.22	-0.42		-0.35	-0.52	-0.16	0.79	0.51	-0.39	-0.38	0.36	0.16
Property Plant And Equipment Gross	0.21	-0.04	0.28	0.09	0.28	1.0	-0.43	0.06	0.67	0.42	-0.38	0.41	-0.19	-0.34	-0.09	0.04	-0.35		0.37	-0.58	-0.32	0.24	0.19	0.19	0.17	-0.11
Total Current Assets	0.97	0.39	0.31	0.42	0.93	0.37	-0.98	-0.09	0.65	0.99	0.39	1.0	0.4	-0.63	0.51	0.38	-0.52	0.37		-0.35	-0.45	-0.47	0.37	0.38	0.4	-0.09
Short Term Debt	-0.23	-0.03	-0.18	-0.07	-0.14	-0.58	0.34	-0.15	-0.33	-0.34	0.27	-0.36	0.03	-0.12	-0.06	0.04	-0.16	-0.58	-0.35		-0.17	-0.43	0.05	0.06	-0.68	-0.04
Short Term Investments	-0.48	0.06	-0.38	-0.42	-0.6	-0.32	0.49	0.3	-0.41	-0.5	-0.33	-0.44	-0.2	0.87	-0.2	-0.39	0.79	-0.32	-0.45	-0.17		0.59	-0.45	-0.45	0.3	0.18
Non Currrent Assets Other	-0.53	-0.45	-0.4	-0.56	-0.55	0.24	0.44	0.64	-0.18	-0.47	-0.43	-0.45	-0.62	0.67	-0.42	-0.7	0.51	0.24	-0.47	-0.43	0.59		-0.68	-0.69	0.24	0.45
Common Stock Total Equity	0.28	0.56	0.59	0.57	0.33	0.19	-0.36	-0.83	0.24	0.38	-0.19	0.37	0.51	-0.56	0.32	0.86	-0.39	0.19	0.37	0.05	-0.45	-0.68		1.0	-0.08	-0.87
Common Stock	0.28	0.56	0.6	0.58	0.32	0.19	-0.36	-0.84	0.24	0.38	-0.2	0.37	0.52	-0.57	0.32	0.86	-0.38	0.19	0.38	0.06	-0.45	-0.69	1.0		-0.08	-0.87
Net Tangible Assets	0.34	0.47	0.28	0.31	0.18	0.17	-0.36	0.12	0.3	0.36	-0.03	0.38	0.39	0.2	0.23	0.0	0.36	0.17	0.4	-0.68	0.3	0.24	-0.08	-0.08		0.15
Retained Earnings Total Equity	0.05	-0.51	-0.56	-0.46	0.03	-0.11	0.05	0.86	0.01	-0.08	0.53	-0.09	-0.43	0.32	-0.18	-0.73	0.16	-0.11	-0.09	-0.04	0.18	0.45	-0.87	-0.87	0.15

Click cells to compare fundamentals

Immunic Account Relationship Matchups

Immunic fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	66.0M	167.9M	139.1M	127.8M	54.3M	81.3M
Other Current Liab	343K	4.7M	585K	8.2M	18.9M	19.9M
Total Current Liabilities	7.1M	8.4M	11.4M	13.1M	24.7M	26.0M
Total Stockholder Equity	58.4M	158.8M	127.1M	113.7M	28.9M	27.5M
Property Plant And Equipment Net	713K	1.1M	1.1M	1.8M	1.8M	1.4M
Net Debt	(28.8M)	(126.8M)	(86.3M)	(105.2M)	(45.3M)	(47.6M)
Retained Earnings	(59.9M)	(103.9M)	(196.9M)	(317.3M)	(410.9M)	(390.3M)
Accounts Payable	2.4M	3.7M	3.7M	4.3M	5.1M	3.9M
Cash	29.4M	127.5M	86.9M	106.7M	46.7M	64.0M
Non Current Assets Total	33.7M	34.1M	34.1M	1.9M	1.8M	1.7M
Cash And Short Term Investments	29.4M	127.5M	86.9M	116.4M	46.7M	66.0M
Common Stock Shares Outstanding	7.7M	15.7M	23.7M	31.8M	44.3M	46.5M
Liabilities And Stockholders Equity	66.0M	167.9M	139.1M	127.8M	54.3M	81.3M
Non Current Liabilities Total	520K	679K	584K	992K	639.0K	607.0K
Other Current Assets	2.9M	1.2M	18.1M	9.5M	5.2M	4.1M
Other Stockholder Equity	53.7M	266.8M	324.2M	427.9M	436.1M	245.3M
Total Liab	7.6M	9.1M	12.0M	14.1M	25.4M	26.6M
Property Plant And Equipment Gross	713K	1.1M	1.1M	1.8M	1.8M	1.4M
Total Current Assets	32.2M	133.7M	105.0M	125.9M	52.5M	70.8M
Accumulated Other Comprehensive Income	(1.4M)	(4.1M)	(252K)	3.0M	3.8M	3.9M
Non Currrent Assets Other	108K	37K	42K	43K	38.7K	36.8K
Net Tangible Assets	25.4M	125.8M	94.1M	113.7M	130.7M	80.6M
Retained Earnings Total Equity	(59.9M)	(103.9M)	(196.9M)	(317.3M)	(285.6M)	(299.8M)
Capital Surpluse	119.6M	266.8M	324.2M	427.9M	492.1M	326.3M
Non Current Liabilities Other	520K	679K	584K	992K	1.1M	1.2M
Property Plant Equipment	80K	203K	1.1M	294K	264.6K	251.4K
Other Assets	37K	42K	943K	43K	49.5K	47.0K
Net Receivables	408K	1.6M	2.2M	2.7M	703K	1.3M
Net Invested Capital	58.4M	158.8M	127.1M	113.7M	28.9M	27.5M
Net Working Capital	25.2M	125.3M	93.6M	112.8M	27.8M	26.4M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Immunic offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Immunic's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immunic Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immunic Stock:

How To Invest In Immunic

Details

Is Immunic Stock a good investment?

Details

What is Immunic's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment.

For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.

You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Complementary Tools for Immunic Stock analysis

When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.

	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges
	Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets

Is Immunic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunic. If investors know Immunic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.11)

Return On Assets

(0.68)

Return On Equity

(1.31)

The market value of Immunic is measured differently than its book value, which is the value of Immunic that is recorded on the company's balance sheet. Investors also form their own opinion of Immunic's value that differs from its market value or its book value, called intrinsic value, which is Immunic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunic's market value can be influenced by many factors that don't directly affect Immunic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Immunic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Immunic Other Assets vs Current Deferred Revenue Analysis

Other Assets vs Current Deferred Revenue

Other Assets vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Other Assets

Current Deferred Revenue

Immunic fundamental ratios Correlations

Immunic Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Immunic fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Immunic Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock	+ 1.0	Common Stock Total Equity
Cash And Short Term Investments	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash
Total Current Assets	+ 0.97	Total Assets

Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Total Current Assets	- 0.98	Net Debt
Net Debt	- 0.95	Total Assets
Net Debt	- 0.94	Total Stockholder Equity
Other Stockholder Equity	- 0.88	Retained Earnings